

INDEX

Note: Page numbers in *italics* indicate figures.
Page numbers followed by a “t” indicate tables.

- Abdominal surgery, 213
- Accessory muscles, use in breathing, 59, 262
- ACE (angiotensin-converting enzyme) inhibitors, 240-241
- Acid-base status, 69, 70, 263
- Acidosis, 47, 70. See also *Respiratory acidosis*.
- Acute bronchitis, 52t
- Acute hypercapnic respiratory failure, 261
- Acute Physiology and Chronic Health Evaluation (APACHE) III scores, 257
- Adenosine, 239
- Adenosine monophosphate, cyclic. See *Cyclic AMP*.
- Advair/Advair Diskus, 143, 178-182, 179t, 187-191.
 - See also *Fluticasone/salmeterol*.
- Advanced-care planning, 277-279
- Advanced directives, 266, 277-278
- Aerobec, 170t
- Aerobec Forte, 170t
- Aerobic exercise training, 116
- Aerobid, 171t
- Aerosol devices, selecting, 194-195, 196t-197t
- Age of onset, COPD vs asthma, 53t
- Aging
 - cognitive decline related to, 243-244
 - as COPD risk factor, 21, 23, 81
 - lung changes due to, 62
 - mortality from exacerbations and, 257
- Air pollution, as COPD risk factor, 21, 22-23, 44, 258t
- Air travel, oxygen therapy and, 123
- Airflow limitation, 34-38, 38t, 43-44
 - in asthma vs COPD, 35t, 52
 - breathlessness and, 54
 - chronic, in COPD, 51
 - in COPD definition, 6, 17, 51, 127, 226
 - in COPD diagnosis, 34-36, 38t, 51, 53t, 60
 - defined, 36
 - factors contributing to, 34, 35t, 127
 - flow-volume loops, 66, 67
 - lung volumes and, 66-67, 68
 - in other conditions, 52-53
 - reversibility of
 - bronchodilators and, 64-65
 - in COPD diagnosis, 64-65
 - partial, 37t, 51
 - spirometry as test of, 60-63, 61, 62
 - staging of COPD based on spirometry, 38t, 60-62
- Airflow obstruction, 32-34
 - bacterial colonization as factor in, 258
 - in chronic bronchitis, 17, 32
 - corticosteroid impact on, 173
 - FEV₁/FVC ratio decrease in, 62, 63
 - flow volume curve for, 67
 - index (BODE index), 39
 - pathophysiology of, 32-34
 - reversibility of, partial, 37t
 - surgical improvement of, 214, 215
- Airolin, 136t

Aiomir, 136t
 Airway bacterial colonization, 55, 258, 258t, 259
 Airway hyperreactivity, 24
 Airway hyperresponsiveness, 44, 45
 Airway inflammation, 34, 35t, 88
 airflow limitation and, 34, 35t, 38
 in asthma vs COPD, 34, 35t
 cells involved in, 36t
 environmental factors in, 43
 small airways, 40-41, 52, 127
 Airway obstruction, 32-34. See also *Airflow obstruction*.
 Airway smooth muscle
 bronchodilator impact on, 128, 129, 147
 hyperplasia of, 34
 proliferation of, 135
 Airways resistance, increased, 37t
 Albuterol, 136t
 combined with anticholinergic (ipratropium), 161, 162-163, 181-182
 Albuterol/ipratropium, 161, 162-163, 181-182
 Albuterol/salbutamol agents, 136t-137t
 Alkalosis, 238, 240
 Allergies, in asthma, usual presence of, 53
 α_1 -antitrypsin deficiency, 23, 44
 in emphysema, 32
 screening/monitoring for, 74
 Alpha-1 Association, 281
 $\alpha\beta 2$ nicotinic acetylcholine receptor partial agonist (varenicline), 100, 103-107
 α -Blockers, 241
 Alupent, 138t
 American Academy of Allergy, Asthma, and Immunology, 281
 American Academy of Family Physicians (AAFP), 281
 American Association for Respiratory Care (AARC), 281
 American College of Chest Physicians (ACCP), 281
 American Lung Association (ALA), 282
 American Thoracic Society (ATS), 17, 282
 ATS/ERS definition of COPD, 17, 225-226, 238
 ATS/ERS exacerbation classification, 257
 ATS/ERS guidelines, 198, 226, 227
 ATS/ERS position paper on diagnosis and treatment, 256, 257
 Amlodipine, 237
 AMP (adenosine monophosphate), cyclic, 128, 129, 133, 147
 Anabolic hormones, 45
 Anabolic steroids, 241
 Anemia, 68
 Angina, 116, 239
 Angioplasty, 239
 Angiotensin-converting enzyme (ACE) inhibitors, 240-241
 Angiotensin II receptor antagonists, 240
 Anorexia, 56
 Anti-inflammatory medications, 88
 corticosteroids, 128-129, 167
 methylxanthines as, 230
 phosphodiesterase-4 (PDE₄) inhibitors, 199-201
 Anti-protease function, 23
 Antibiotics, for exacerbations of COPD, 198, 231, 258, 264
 Anticholinergics, 88, 147-161, 149t. See also *Ipratropium*; *Tiotropium*.
 action mechanism, 128, 129, 147
 agents and dosage, 148, 149t
 anticholinergic/ β_2 -agonist combinations, 161, 162-163, 179t, 229
 anticholinergic/methylxanthine combinations, 193
 effects of, 147-148, 160
 Anticholinergics (*continued*)
 efficacy, 148, 150, 160
 for exacerbations of COPD, 198, 231, 258, 263
 inhaled, cardiovascular risk and, 159, 160-161
 inhaled vs systemic, 148
 key points, 160
 safety analysis, 160-161
 side effects, 148, 160
 Antidepressants, 243, 246
 Antihypertension agents, 240-241
 Antioxidants, 37, 200t, 201
 Antiplatelet-aggregation therapies, 238
 Antiproteinases, 37
 Antitussives, 200t
 Anxiety, 242-243
 management/treatment of, 88, 117, 243
 sleep disorders associated with, 245
 Anxiolytics, 243, 246
 APACHE III scores, 257
 Apnea, obstructive sleep, 246
 Arformoterol (Brovana), 140t, 145-146
 adverse events, 145-146
 effects of, 145
 Arrhythmias, 147, 191, 258t, 267t
 Arterial blood gases, 69, 70, 72
 in exacerbations, 262, 263
 preoperative, 213
 Arthritis
 in chest wall joints, 23
 disabling, pulmonary rehabilitation cautions for, 116
 Asmabec, 170t
 Asmasal, 136t
 Aspirin, 238
 Assessment, clinical, 53-72. See also *Diagnosis of COPD*.
 of exacerbations, 261-263
 of symptoms, 53-56, 55t
 Assisted ventilation. See *Oxygen therapy*; *Ventilation support*.
 Asthma
 age of onset, 53t
 airway inflammation in, 34, 35t
 chronic, COPD and, 24, 226
 DLCO in, 69
 exacerbations of, 258, 262
 severe, 35t
 short-acting β_2 -agonist use in, 134
 smoking as aggravating factor, 34
 vs COPD, 35t, 52-53, 53t, 54
 Atopy, 45
 Atropine, 148
 Atrovent. See *Ipratropium bromide*.
 Auscultation of the chest, 58
 Azmacort. See *Triamcinolone*.

 B lymphocytes, 36t
 Bacterial infections, 258, 258t, 259, 259t, 264
 gram-negative, 264
 Bacterial pneumonia, immunization for, 88
 Bambec (bambuterol), 137t
 Bambuterol (Bambec), 137t
 BAY-19-8003, 201
 Beclazone, 170t

- Beclodisk, 170t
 Beclorforte, 170t
 Beclomet, 170t
 Beclomethasone (beclometasone), 65, 170t
 Beclovent, 170t
 Becodisk, 170t
 Becotide, 170t
 Behavior change, motivating, 15
 for smoking cessation, 93, 96-99, 98t
 Benzodiazepine, 243
 Berodual, 179t
 Berotec (fenoterol), 137t
 β -Blockers
 for angina, 239
 combined with α -blockers, 241
 for right-heart failure, 238
 for systemic hypertension, 240
 β_2 -Adrenergic agonists. See *β_2 -agonists*.
 β_2 -Adrenergic receptors, 128, 129, 133
 β_2 -Agonists, 133-147
 action mechanism, 128, 129, 133, 135, 147
 adverse effects, 146-147
 cardiovascular, 147
 sleep disorders, 245
 systemic, 146-147
 β -blockers and, 240
 β_2 -agonist/anticholinergic combinations, 161-164, 162-163, 165, 179t, 229
 β_2 -agonist/corticosteroid combinations, 173, 178-191, 179t, 244-245
 β_2 -agonist-methylxanthine combinations, 193
 dosage
 minimal effective, as best, 141
 negative dose relationship, 141, 144-145
 drug interactions, 193t
 for exacerbations of COPD, 263
 key points, 147
 long-acting (LABA), 88, 89, 134-143, 140t, 147, 229
 in combination with corticosteroids, 178-191, 179t, 203, 244-245
 duration of action, 134-135
 effects of, 135
 efficacy, 135-143, 142
 side effects of, 135
 nonbronchodilator effects of, 133
 role in treatment, 229
 safety and tolerability, 147
 short-acting, 133-134, 136t-139t, 147
 effectiveness in COPD, 134
 loss of effectiveness in asthma, 134
 Bicarbonate, 69, 70
 Bicycle ergometry, 116, 239
 Bioelectric impedance, 119-120
 Bisphosphonate therapy, 242t
 Bitolterol (tornalate), 139t
 Blood gases, arterial, 69, 70
 Blood viscosity, increased, 235, 238, 240
 BMI. See *Body mass index*.
 BODE (body mass index, airflow obstruction, dyspnea, exercise performance)
 Index, 39
 Body mass index (BMI)
 in assessing COPD, 227
 low, in COPD, 45
 low, osteoporosis risk and, 241
 Body mass index (BMI) (*continued*)
 mortality, impact on, 111, 118, 119, 257
 weight categories defined by, 119
 Body plethysmograph, 66-67
 BOLD (Burden of Lung Disease) study, 20-21
 Bone mineral loss, 56
 corticosteroids and, 167, 177
 Borg Scale, Modified, 54, 55t
 Bosentan, 237
 Boyle's law, 66
 Breath sounds/pattern, 57-58
 Breathaire, 139t
 Breathlessness. See *Dyspnea*.
 BreathWorks (organization), 282
 Brethine, 139t
 Bricanyl, 139t
 Bronchial hyperresponsiveness, 44, 45
 Bronchiectasis, 53
 Bronchiolitis, 33-34
 Bronchitis, acute, 52t
 Bronchitis, chronic. See *Chronic bronchitis*.
 Bronchodilation, production of, 128, 129
 Bronchodilators, 88, 131-161, 229-230. See also *specific bronchodilator classes*.
 action mechanism of, 128, 129, 131
 aggressive, first-line therapy with, 131-132
 bronchodilator combinations, 161-167
 key points, 167, 203, 229-230
 lung function with, 161-167, 162-163, 164
 bronchodilator/corticosteroid combinations, 173, 178-191
 clinical effects, 131-132, 132
 for exacerbations. See *Exacerbations of COPD*.
 guidelines, 229-230
 key points, 167, 202-203
 long-acting, 130
 lung function improvement with, 131-132, 132
 overview, 131-133, 229-230
 responsiveness, assessing, 132-133
 reversibility of airflow obstruction with, 37t, 39-42
 in diagnosis, 64-65, 65t
 role in disease management, 229-230
 short-acting, 130
 testing, 64-65
 guidelines for, 65t
 types of, 128
 anticholinergics, 147-161
 β_2 -adrenergic agonists, 133-147
 methylxanthines, 191-194
 Bronchospasms, adenosine and, 239
 Bronkometer, 137t
 Bronkosol, 137t
 Brovana. See *Arformoterol*.
 Bruising, corticosteroids and, 169, 177
 Budesonide/formoterol (Symbicort), 169, 182-187, 183, 185
 long-term efficacy and tolerability, 184-187
 in SHINE and SUN trials, 186-187
 Budesonide (Pulmicort), 171t
 adverse effects, 169
 clinical studies, 168-169, 172, 175
 Bullae, 77, 78, 214, 216
 Bullectomy, 214-215, 216t-217t
 Bullous disease, 66

Bupropion, for smoking cessation, 100, 103, 104t
 vs varenicline, 105-106, 105

Burden of disease, 24-26
 Burden of Lung Disease (BOLD) study, 20-21
 costs, economic and societal, 24-26, 25, 27
 underestimation of, 18

Buventol, 136t

Bypass surgery, 239-240

C-reactive protein, 239

Cachexia, 47, 119

Calcitonin, 242t

Calcium antagonists, 241

Calcium channel blockers, 237, 239

Calcium supplements, 242t

Cancer, 244-245
 lung, 244-245

Carbon monoxide (CO) diffusion, 68-69, 118

Cardiac stress testing, 239

Cardiology, referrals for, 89, 91t

Cardiovascular disorders, 235-241, 236t

Cardiovascular risk, nicotine-replacement therapy and, 101-103

Cardiovascular side effects
 of β_2 -agonists, 147
 of inhaled anticholinergics, 159, 160-161

Cardiovascular signs of COPD, assessment of, 58-59

Cardiovascular surgery, 213

Catabolic state, chronic, 45

Cataracts, systemic corticosteroids and, 167

Causes of COPD. See *Risk factors for COPD*.

Centriacinar (centrilobular) emphysema, 32

Cerebrovascular disease, 238

CFC (chlorofluorocarbon) propellants, 196t-197t

Chantix. See *Varenicline*.

Chemokines, 199

Chemotherapy, 244

Chest
 percussion and auscultation of, 58
 radiography of, 74-78, 75, 76
 wall joints, arthritis in, 23

Chest pain and tightness, 56, 145

Childhood respiratory infections, 44

Cholelyl, 192t

Chronic bronchitis, 32, 33, 38, 40
 in COPD diagnosis, 51, 52t
 in COPD pathology, 32, 33
 corticosteroid/bronchodilator combinations for, 181, 191
 cost of, 25
 definition of, 56
 inclusion in COPD definition, 17
 pathologic changes in, 32, 33, 40-41
 sputum production in, 56
 vs emphysema, 32, 33, 40-41

Chronic Respiratory Disease Index Questionnaire (CRDQ), 73, 114

Cigarette smoke. See *Smoking*.

Cilomast, 199-201

Clinical assessment. See *Assessment, clinical*.

Clinical trials. See also *specific agents and therapies*.
 of corticosteroid/bronchodilator combinations, 178-191
 of corticosteroids, 168-177
 EUROSOP (inhaled budesonide), 168-169

Clinical trials (*continued*)
 INSPIRE study, 270-272
 ISOLDE trial (inhaled fluticasone), 168, 172
 Lung Health Study, 93, 94, 168, 169-170
 NETT (National Emphysema Treatment Trial), 215
 of oxygen therapy, 121, 122
 SHINE trial, 186-187
 SUN trial, 186-187
 of surgery, 215
 TORCH trial (COPD health), 128, 176-177, 187-191
 TRISTAN (inhaled steroids), 168, 178-182, 180
 UPLIFT study (tiotropium), 158-159, 159

Cognitive decline, 243-244

Coma, 267t

Combination therapy, 230-231. See also *specific agents and classes of agents*.
 bronchodilator combinations, 161-167
 corticosteroid/bronchodilator, 178-191
 with methylxanthines, 193
 rationale for, 128, 129t, 161

Combivent, 179t

Comorbid conditions, 57, 60, 235-254, 236t
 cancer, 244-245
 cardiovascular disorders, 235-241, 236t
 exacerbations of COPD and, 256, 262
 mental health disorders, 242-244
 musculoskeletal disorders, 241-242
 nutritional disorders, 247-248
 risk in COPD, 235
 sexual dysfunction, 248-249
 sleep disorders, 245-246

Computed tomography (CT), 76-78, 77, 214, 216

Congestive heart failure, 257

Consultation and referral, 90, 91t

COPD (chronic obstructive pulmonary disease)
 definition of, 17, 31, 127, 225-226, 238
 economic and social cost of, 24-26, 25, 27
 introduction, 13-15
 as multicomponent, heterogenous disease, 83-86, 88, 226
 resources and associations, 281-284
 stages of, 20, 38t, 62
 vs asthma, 35t, 52-53, 53t

COPD Foundation, Inc., 282

COPD-Support, Inc., 282

Coping skills, 117

Cor pulmonale, 58, 236t, 237-238, 257

Coronary artery bypass, 239-240

Coronary artery disease, 239

Coronary atherosclerosis, 238

Coronary heart disease, 57, 60

Corticosteroids, 167-178
 action mechanism in COPD, 128-129
 adverse effects, 167, 169, 177, 241
 agents and dosages, 170t-171t
 combination preparations, 179t
 anti-inflammatory effects, 128-129, 167
 clinical studies, ISOLDE, 168, 172
 COPD exacerbation by, 47
 COPD exacerbations reduced by, 129
 COPD management, role in, 129
 corticosteroid/ β_2 -agonist combinations, 178-191, 179t, 230, 244-245

Corticosteroids (*continued*)

- corticosteroid/bronchodilator combinations, 173, 178-191, 179t, 180, 230-231
- exacerbation prevention with, 269-272
 - key points, 191, 203
 - drug interactions, 193t
- for exacerbations of COPD, 167, 231, 264
 - antibiotics, 264
 - guidelines for, 230
 - health status, impact on, 129
- inhaled, 88, 89, 167-178, 170t-171t
 - adverse effects, 177
 - disease progression, lack of effect on, 169-173, 174
 - effect on exacerbations and health status, 167-169, 172, 177
 - effect on hospitalizations, morbidity, and mortality, 173-177, 178
 - effects on airflow, 173
 - efficacy of, 167-169, 172
 - initiation of therapy, 177
 - key points, 177-178, 203
 - reversibility of airflow limitation with, 65
- systemic, 47, 167
 - adverse effects, 167, 203, 241, 264
 - beneficial for COPD exacerbations, 167, 231, 264
 - testosterone levels, impact on, 248

Costs of COPD, 24-26, 25, 27

Cough, 54-56

- in bronchitis, 51, 52t
- in COPD diagnosis, 51, 52t
- as COPD symptom, 54-56
- as indicator for COPD evaluation, 82
- productive, 51, 54, 55-56
- sleep disruption due to, 245
- "smoker's," 51

CRDQ (Chronic Respiratory Disease Index Questionnaire), 73, 114

Crepitations, 58

CT. See *Computed tomography*.

Cyanosis, 58, 262

Cyclic AMP, increase with bronchodilators, 128, 129, 133, 147

Cystic fibrosis, airflow limitation in, 53

Cytochrome P-450, 243

Cytokines, 21, 45, 60, 239

Dead space, 71, 260t, 261

Death, consideration/acceptance of, in end-stage disease, 277-279

Deconditioning, 11, 47, 241

Definition of COPD, 17, 31, 127, 225-226, 238

Depression, 56, 57, 60, 242-243

- management/treatment of, 88, 100t, 117, 243
- sleep disorders and, 245
- as smoking withdrawal symptom, 100t

Detection, early. See *Prevention and early detection*.

Developing countries

- air pollution and COPD risk in, 22-23
- costs of COPD, 25-26
- prevalence of COPD in, 18-19

DEXA scans, 242t

Diabetes, 57, 60

nicotine-replacement therapy and, 103

Diabetic nephropathy, 240

Diagnosis of COPD, 51-80, 202. See also *Prevention and early detection*.

- airflow limitation in, 34-36, 38t
- ATS/ERS position paper on diagnosis, 256

Diagnosis of COPD (*continued*)

- clinical assessment, 53-72
 - arterial blood gases, 69, 70
 - bronchodilator reversibility, 64-65, 65t
 - cardiovascular signs, 58-59
 - chest percussion/auscultation, 58
 - exercise testing, 69-71
 - flow-volume loops, 66, 67
 - gas transfer/diffusing capacity, 68-69
 - peak expiratory flow (PEF), 63-64
 - physical examination, 57-60
 - pulmonary function tests, 60-69
 - pulmonary vascular pressure, 72
 - respiratory muscle function, 71-72
 - respiratory signs, 57-58
 - right ventricular function, 72
 - sleep studies, 72
 - spirometry, 60-63, 61, 62, 82-83, 127
 - static lung volumes, 66-67, 68
 - symptoms, 53-56, 55t
 - systemic effects, 59-60
 - conditions evaluated in, 51-53
 - criteria, 31, 34-36
 - differential diagnosis, 52-53, 53t
 - follow-up/monitoring, 72-78
 - key indicators, 52t
 - multicomponent, heterogenous profile, 83-86, 88, 226
 - overview, 51-53, 52t, 82
 - post-bronchodilator airflow obstruction, 31, 38t
 - screening questionnaire, 84t-85t
 - staging based on spirometry, 38t, 60, 62
 - underdiagnosis, 18
- ### Diaphragm
- action in breathing, 58
 - diaphragmatic breathing, 117
 - muscle mass and contractility, 118
 - radiography of, 74, 75
 - surgery proximity to, complication and, 213
 - weight loss/muscle wasting and, 118
- ### Diarrhea, 198
- ### Dietary intake. See *Nutrition*.
- ### Dietician, 89, 115
- ### Diffusing capacity
- of carbon monoxide (DLCO), 68-69, 214
 - decreased, 37t, 118
- ### Digitalis, 238
- ### Disease progression
- altering, 87-88
 - corticosteroid therapy, lack of effect on, 169-173, 174
 - factors related to, 82
 - pulmonary rehabilitation impact on, 114-115
 - smoking cessation impact on, 87
- ### Distal acinar (paraseptal) emphysema, 32
- ### Diuretics
- for cardiovascular disorders, 238, 240
 - sleep disorders and, 246
 - thiazide, for osteoporosis, 242t
- ### DLCO (diffusing capacity of carbon monoxide), 68-69
- ### Dobutamine infusions, 239
- ### Doppler echocardiography, 72, 78
- ### DPIs. See *Dry-powder inhalers*.

Drug interactions, 191, 193t, 194
Drug-resistant organisms, antibiotic use and, 198
Dry-powder inhalers (DPIs), 136t-140t, 149t, 150, 170t-171t, 179t
 device selection for, 194-195, 197t
DuoNeb, 179t
Duovent, 179t
Dutch/Belgian Tiotropium Study Group, 152, 153
“Dutch hypothesis,” 45
Dynamic hyperinflation, 37t, 39
Dyspnea, 52t, 53-56
 in COPD diagnosis, 52t
 in coronary artery disease, 239
 exacerbations of COPD and, 256, 267t
 exertional, 52t, 53t, 134
 hyperinflation and, 39
 factors affecting, 54
 FEV₁ level in, 54
 hospitalization for, 267t
 nutritional disorders and, 247
 progressive, 52t
 pulmonary function tests, 60-69, 262
 quantification of, 54, 55t
 relieving
 bronchodilators, 133, 134, 147, 153-154, 154
 corticosteroid/bronchodilator combinations, 164, 181, 184
 exercise training, 116-117
 mechanical ventilation, 231
 pulmonary rehabilitation, 112, 112t, 113
 surgical procedures, 214, 215
 scales for, 54, 55t
 transition dyspnea index (TDI), 181
Early detection. See *Prevention and early detection*.
East London Study, 257
ECG (electrocardiography), 72, 239
Echocardiography, 72, 78, 239
Economic costs of COPD, 24-26, 27
 breakdown of, 27
 direct and indirect, 24-26
 estimated cost (2007), 25
Eczema, 53t
Edema, 58, 59, 238
Education, patient. See *Patient education*.
Elastic recoil, 36-38, 40-41
 decreased
 in COPD, 37t, 38
 hyperinflation and, 38
 in forced exhalation, 36-38
 static lung volumes and, 66
Elastolytic proteases, 201
Electrocardiography (ECG), 72, 239
Elixophyllin, 192t
Emotional function, 113, 114, 141, 277
Emphysema, 52
 in COPD definition, 17
 in COPD pathology, 32, 33, 52
 in multicomponent, heterogeneous presentation, 86, 88
 cost of, 25
 defined, 52
 elastic recoil in, 37-38, 40-41
 pathologic changes in, 32, 33, 40-41

Emphysema (*continued*)
 radiographic signs of, 74-76, 75, 77
 vs chronic bronchitis, 32, 33
End-of-life care, 91t, 227-229
End-stage disease, managing, 277-279
Endothelin receptor antagonists, 237
Endotracheal intubation, 265, 277, 278
Endurance training, 116
Eosinophils, 35t, 36t, 259, 259t
Eotaxin, 35t
Epidemiology of COPD, 17-21
 mortality rates and, 18-20, 19, 20
 prevalence rates, 18-21
 risk factors, 21
Epithelial cells, 36t
Erectile dysfunction, 248-249
Erythrocytosis, 235, 238
Estrogen
 anti-inflammatory effect of, 24
 deficiency, osteoporosis and, 241
 replacement therapy, 242t
European Respiratory Society (ERS), 17, 282. See also *American Thoracic Society, ATS/ERS subentries*.
EUROSOP (clinical trial), 168-169
Exacerbations of COPD, 255-275
 antibiotic treatment for, 198, 231, 258, 264
 assessment of, 261-263
 clinical findings in, 256
 costs of, 255
 definition, 256
 diagnosis of, 261-263
 etiology of, 257-258, 258t
 guidelines regarding, 261t
 health status, impact on, 89, 231
 impact of, 255
 life-threatening, 266t
 preparing for decisions in, 278
 management of, 89, 261-267
 antibiotics, 264
 assessment, 261-263
 bronchodilator therapy, 263, 265
 general principles, 261t
 home therapy vs hospital or ICU, 266-267, 267t
 invasive mechanical ventilation, 265-266, 266t
 mobilization/clearance of secretions, 264-265
 noninvasive mechanical ventilation, 265
 oxygen therapy, 263
 systemic corticosteroids, 264
 mortality from, 255, 257
 noninvasive ventilation for, 231
 overview, 231
 pathology of, 258-259, 259t
 prevention of, 267-272, 269t
 inhaled steroid/anticholinergic combinations, 269-272, 271
 other treatments, 272
 pulmonary physiology of, 260-261, 260t
 reducing
 bronchodilators, 143, 148, 151, 158, 160, 263, 265, 269t
 corticosteroid/bronchodilator combinations, 164-165, 187-188, 191, 231, 269-272, 271
 corticosteroids, 130, 167, 168, 172, 177, 230, 264, 269t

- Exacerbations of COPD, reducing (*continued*)
 goal of, 227-229
 pharmacotherapy, 127
 pulmonary rehabilitation, 114, 203
 severity, classification of, 256-257
- Exercise, 88, 116-117
 dyspnea in, 39, 52t, 53t, 134
 oxygen therapy during, 121-122, 123
 testing, 69-71
 training, 116-117, 203
 endurance training, 116
 in osteoporosis management, 242t
 strength training, 117
- Exercise capacity
 assessing, 69-71
 deconditioning and, 47, 241
 increasing
 as goal, 227
 through pharmacotherapy, 143, 155-157, 156, 157
 through pulmonary rehabilitation, 112t, 113
 through surgery, 214, 215
- Exercise tolerance, 56, 59
 improving
 bronchodilator, 148
 exercise training, 116-117
 pulmonary rehabilitation impact on, 112t, 113
 reduction in, 45
- Expiratory flow rate, 66, 67, 215
- Fagerstrom test for nicotine dependence, 101, 102t
- Family/genetic history. See also *Genetic factors*.
 of asthma, 53t
 of COPD, 57, 81
- Family members, in pulmonary rehabilitation support groups, 117
- Fat-free mass (FFM)
 FFM index (FFMI), 120
 measurement of, 119-120
 reduction in, 45, 46t, 118-120
 as indication for nutritional intervention, 120
- Fatigue
 as COPD symptom, 56, 59
 nutritional disorders and, 247
- Fenoterol (Berotec), 137t
- Fenoterol/ipratropium, 179t
- FEV₁ (forced expiratory volume in 1 second), 61-63, 61
 aging impact on, 23, 62
 calculating and expressing, 61
 corticosteroid impact on, 64-65
 impaired, 61-63, 62
 increased, post-bronchodilator, 39-42, 42
 measuring, 61-63
 normal/predicted, 61-62, 61, 226
 predicted in COPD stages, 130
 prediction nomograms, 86, 87
 pharmacotherapy impact on, 129t
 post-bronchodilator, 39-42, 42, 64-65
 assessing, 132-133
 in COPD diagnosis, 61, 64-65
 increased QOL with, 129t
 spirometric classification based on, 38t, 61-63
 as severity stage indicator, 38t, 61-63, 62
- FEV₁ (forced expiratory volume in 1 second) (*continued*)
 SGRQ and, 73
 smoking and, 43-44, 44
 smoking cessation impact on, 93, 94
 surgery impact on, 215, 220
 surgical risk and, 214
 vs peak expiratory flow (PEF), 63-64
- FEV₁ (forced expiratory volume in 1 second)/FVC (forced vital capacity) ratio, 61-63
 airflow limitation definition by, 18, 226
 calculating and expressing, 61
 in COPD diagnosis, 31, 51, 61-63, 62, 226
 impaired, 61-62, 62
 normal/predicted, 61, 61
 predicted in COPD stages, 130
 prediction nomograms, 86, 87
 post-bronchodilator, 31, 38t, 51
 for smokers, 18, 44
- FFIS (formoterol fumarate inhalation solution), 140t, 146
- FFM. See *Fat-free mass*.
- Fibrosis, 32, 33, 38
- Filair, 170t
- Fish oil, 247
- "Five A's", smoking cessation strategy, 94-96, 96t
- "Five R's", smoking cessation motivation, 98, 98t
- Flixotide, 171t
- Flovent, 171t
- Flovent Diskus, 171t
- Flow-volume loops, 63, 66, 67
- Flunisolide, 171t
- Flunitec, 171t
- Fluticasone, 89, 171t
 beneficial effect on survival, 173, 176-177
 inhaled
 effect on FEV₁, 174
 in ISOLDE trial, 168, 172
 in TRISTAN study, 168, 178-182, 180
- Fluticasone propionate, 171t
- Fluticasone/salmeterol (Advair/Advair Diskus), 178-182, 179t, 203
 anti-inflammatory effects, 178
 approval for COPD with chronic bronchitis (250/50), 181, 191, 269
 for COPD exacerbations, 269-272, 271
 COPD survival and mortality studies, 187-191, 188, 189, 190
 effects of, 179-182, 180, 231
 in INSPIRE study, 270-272
 in TORCH trial, 187-191, 188, 189, 190
 in TRISTAN study, 178-182, 180
 vs tiotropium, 270-272
- Fluvoxamine, 243
- Follow-up and monitoring, 72-78
 after hospital discharge, 266-267, 268t
 of COPD patients, 72-78
 health status, 73
 other assessments, 73-74
 of smoking cessation, 97, 99
- Foradil, 135, 140t
- Foradil Aerolizer, 135
- Formoterol, 143-145
 in combination with budesonide (Symbicort), 169, 179t, 182-187, 183, 185
 efficacy, 143-145, 144
 enantiomer of. See *Arformoterol*.
 formulations and dosage, 140t

Formoterol (*continued*)
 onset and duration of action, 143
 vs ipratropium, 143-144, 144
 Formoterol/budesonide (Symbicort), 169, 179t, 182-187, 183, 185
 Formoterol fumarate (Foradil Aerolizer), 135
 Formoterol fumarate inhalation solution (FFIS; Perforomist), 140t, 146
 Fractures, vertebral and rib, 242
 Framework Convention on Tobacco Control, 21-22
 FRC (functional residual capacity), 66, 131
 Functional capacity, 86, 213
 Functional residual capacity (FRC), 66, 131
 Functional status, 111, 128
 FVC (forced vital capacity), 61-63, 61
 impaired, 61-62, 62
 improving, 131
 measuring, 61-63
 normal, 61

 Gas-exchange abnormalities, 42-43
 Gas trapping, 66. See also *Hyperinflation*.
 Gases
 arterial blood gases, 69
 transfer/diffusing capacity, 68-69, 118
 Gastroesophageal reflux, 56
 Gender
 mortality from COPD and, 19-20, 19, 20
 prevalence of COPD and, 21, 24
 risk of COPD and, 24
 Genetic factors
 α_1 -antitrypsin deficiency, 23, 44
 candidate genes, 23
 COPD risk and, 23-24, 44
 family history of COPD, 57, 81
 Global Initiative for Chronic Obstructive Lung Disease. See *GOLD*.
 Glucocorticoids, osteoporosis due to use of, 56
 Glucocorticosteroids, inhaled, 130, 203. See also *Corticosteroids, inhaled*.
 GOLD (Global Initiative for Chronic Obstructive Lung Disease), 81, 198, 282
 definition of COPD, 17, 31, 226
 stages of COPD/stepwise management of, 20, 202t
 treatment guidelines, 225, 230
 Gram-negative pathogens, 264
 Gum, nicotine-replacement, 101

H influenzae, 258, 264
Haemophilus influenzae, 258, 264
 Health care utilization, pulmonary rehabilitation impact on, 112t, 114.
 See also *Hospitalizations*.
 Health-related quality of life. See *Quality of life, health related (HRQOL)*.
 Health status, 73
 improving
 goal of, 111, 227-229
 through bronchodilators, 147, 151
 through corticosteroid/bronchodilator combinations, 164-165, 187-188
 through corticosteroids, 129, 167-169, 177
 through lung transplantation, 220
 through pharmacotherapy, 127
 through pulmonary rehabilitation, 111, 112t, 114
 questionnaires, 73, 229
 Healthy Resources (organization), 283
 Heart disease. See *Cardiovascular disorders*.
 Heart murmur, 59

 Heart-related symptoms of COPD, 58-59
 Helium dilution technique, 66
 Hematocrit, 73, 238, 240
 Hemodynamic instability, 262
 Hemoptysis, 55
 History
 of asthma/respiratory illnesses, 57
 of exposure to risk factors, 51, 52t
 family (of COPD), 57, 81
 medical, 53-72, 81-82
 of smoking, 57, 82
 Home care, 89, 91t
 surveillance and oversight in, 243-244
 Home therapy, for exacerbations, 266-267
 Hoover's sign, 58
 Hormone replacement therapy, 242t
 Hospice services, 89, 279
 referral for, 91t
 Hospitalizations
 bronchodilator effect on, 151, 158
 corticosteroid/bronchodilator combinations and, 165-167
 corticosteroid effect on, 173-175, 176
 discharge criteria, 266, 268t
 duration of, 266
 for exacerbations, 266-267
 indications for, 267t
 follow-up assessment, 266-267, 268t
 indications for, 266-267, 267t
 older patients, 21
 pulmonary rehabilitation, effect on, 112t, 114
 Hounsfield units (HU), 77-78
 HRQOL. See *Quality of life, health related (HRQOL)*.
 Human growth hormone, 247
 Hypercapnic respiratory failure, 261, 263
 Hypercapnia, 47, 58, 59, 214
 hospitalization for, 267t
 Hypercarbia
 in advanced COPD, 37t
 in COPD exacerbations, 260t
 Hyperglycemia, 264
 Hyperinflation, 37t, 38-39
 assessing, 58, 59, 66-67, 68, 133
 bronchodilator reduction of, 39-42, 131, 132, 154-155, 155, 160
 dynamic, 37t, 39
 exertional dyspnea and, 39
 increased elastance from, 43
 radiographic signs of, 74, 75
 static, 37t, 39
 surgical treatment for, 215-220
 Hypertension, 240-241
 COPD interaction with, 235
 in COPD patients, 57, 60
 pulmonary, 235-237, 236t
 systemic, 240-241
 treatments for, 236-237
 Hypochloremic alkalosis, 238, 240
 Hyponatremia, 238, 240
 Hypopnea syndrome, 72
 Hypoventilation, 43, 245
 Hypoxemia, 42-43, 227
 assessing for, 58
 in COPD, 37t, 42-43

Hypoxemia (*continued*)
in exacerbations of COPD, 260-261, 260t, 266t
hospitalization for, 267t
life-threatening, 266t
mechanical ventilation for, 266t
oxygen therapy for, 236, 238, 260-261
persistent daytime, 227
pulmonary hypertension and, 235
sleep disorders and, 245
spirometric staging as predictor of, 227
surgical improvement of, 214
Hypoxia, 45-47, 244

IC. See *Inspiratory capacity*.
IC/TLC (inspiratory capacity to total lung capacity), 39
ICAM-1 expression, 259t
ICU admission, 266-267, 267t

IL. See *Interleukins*.
Immunizations, 87-88, 130, 195-198. See also *Vaccinations*.
Immunoregulators, 200t
Immunosuppression, 167
Infections, COPD exacerbations and, 257-258, 258t
Inflammation, 34, 35t
airflow limitation associated with, 34, 35t, 127
cells involved in, 34, 36t
in COPD and asthma, 34, 35t
as COPD component, 37, 52, 86, 88
in COPD definition, 17
environmental factors in, 43
future pharmacotherapies and, 199-201
processes, 32, 33, 199
systemic, 60
impact on nutritional status, 118-119
Influenza, COPD exacerbations and, 258, 269t
Influenza vaccination, 87-88, 130, 195-198, 269t
Inhalation devices, selection of, 194-195, 196t-197t
Inhaled Steroids in Obstructive Lung Disease in Europe (ISOLDE) trial, 168, 172
Inhalers. See *Bronchodilators; Corticosteroids, inhaled*.
Inotropic agents/effect, 191, 238
Insomnia, nicotine replacement therapy and, 101, 104t
Inspiratory capacity (IC)
assessing therapeutic effectiveness with, 133, 154-155
post-bronchodilator, 42, 131, 154-155, 155
Inspiratory capacity to total lung capacity (IC/TLC), 39
Inspiratory reserve volume (IRV), 54, 66
INSPIRE study, 270-272
Inspiry!, 136t
Intensive care unit (ICU), 266-267, 267t
Intercostal myopathy, 167
Interleukins, 35t
COPD exacerbations and, 257, 258-259, 259t
IL-6, 257, 259, 259t
IL-8, 35t, 45, 199, 258-259, 259t
Interventions, 86-89, 117. See also *Management of COPD*.
combined, need for, 86
exacerbation prevention, 269t
nutritional, 47, 120, 247
Intrathoracic pressure swings, 58
Intubation, 265, 277, 278
Invasive mechanical ventilation, 265-266, 266t

Ipratropium, 148, 149t, 160
in combination with albuterol, 148, 179t, 181-182
effectiveness, 148, 150
vs formoterol, 143-144, 144
vs metaproterenol, 148, 150
vs salmeterol, 135-141, 142
Ipratropium/albuterol (Combivent; DuoNeb), 148, 179t, 181-182
Ipratropium bromide (Atrovent), 148, 149t
dynamic hyperinflation reduced by, 131, 132
Ipratropium/fenoterol (Berodual; Duovent), 179t
IRV (inspiratory reserve volume), 54, 66
Ischemic heart disease, 53. See also *Cardiovascular disorders*.
Isotherine (Bronkosol, Bronkometer), 137t
ISOLDE (Inhaled Steroids in Obstructive Lung Disease in Europe) trial, 168, 172
Isoproterenol (Isuprel), 137t
Isuprel (isoproterenol), 137t

Jet nebulizers, 196t

Kyphosis, spinal, 23

LABA. See *Long-acting β_2 -agonists (LABA)*.
Laboratory tests. See *Tests for COPD patients*.
Left-heart failure, 237
Leukotrienes, 199, 248
Levalbuterol (Xopenex), 138t
Life-supportive care, 277-279. See also *End-of-life care*.
Liver enlargement, 58
Living will, ventilation decisions and, 266, 277-278
Lobectomy, 214
Long-acting β_2 -agonists (LABA), 88, 89, 134-143, 140t, 229.
See also *specific agents*.
action mechanisms, 128, 129, 135
adverse effects, 145
agents and dosing, 135, 140t
cautions for, 145-146
duration of action, 134-135
Losartan, 240
“Lung age,” 83, 86, 87
Lung cancer, 244-245
Lung function
aging impact on, 62
assessing/tests for, 60-69
corticosteroid/bronchodilator combinations and, 179-187, 191, 231
corticosteroid impact on, 167-169, 172, 177
pharmacotherapy impact on, 129t
phosphodiesterase-4 inhibitors and, 199-201
post-bronchodilator, 64-65, 131-132, 132
anticholinergics, 151, 158
 β_2 -agonists, 143, 144, 147
bronchodilator combinations, 161-167, 162-163, 164
theophylline and, 191
Lung Health Study, 93, 94, 168, 169-170
Lung parenchyma
alterations of, 35t, 36t, 43
destruction of, 127, 201
Lung pressure-volume curve, 71
Lung resection, 213-214
Lung surgery. See *Surgical therapy*.
Lung transplantation, 220, 221t
Lung volume-reduction surgery (LVRS), 215-220, 218-219
referral for, 91t

Lung volumes
 bronchodilators and, 154-155, 155
 measuring, 66-67, 67, 68
 residual, reduced by bronchodilators, 131, 160
 static, in COPD diagnosis, 66-67, 67, 68

M catarrhalis, 258, 264

Macrophages, 35t, 36t, 43
 in COPD exacerbations, 259, 259t

Malnutrition, 47, 118-120, 241, 247-248

Management of COPD, 81-92. See also *specific therapeutic approaches*.
 algorithm, 83
 assessing response to treatment, 227-229
 bronchodilator role in, 229-230
 comorbid conditions, 235-254
 for COPD stages, 130, 201, 202t, 226-227
 end-stage, 227-229
 exacerbations, management of, 89
 general patient approach in, 81-92
 goals, 111, 127-128, 227-229
 guidelines/overview, 82, 83, 225-233
 key interventions, 14, 202-203
 multicomponent/heterogenous disease presentation, 83-86, 88
 nonpharmacologic therapy, 111-126, 203
 pharmacologic therapy, 127-212
 integration with patient care, 201-203, 202t
 key points on, 129t
 stepped-care approach, 201, 202t
 primary care physicians in, 14-15, 82-83
 screening questionnaire, 84t-85t
 self-management, patient education in, 117
 severe COPD, management of, 89
 smoking cessation and, 93-110, 127
 stable COPD, management of, 86-88
 surgical therapy, 213-224
 team approach in, 89

Mann-Whitney rank sum test, 172

Matrix metalloproteinases (MMPs), 201, 239

Maxair (pirbuterol), 138t

MDIs (metered dose inhalers), 179t, 194-195, 197t

Mechanical ventilation. See *Oxygen therapy; Ventilation support*.

Medical care, cost-breakdown for COPD, 25, 27

Medical history, 53-72, 81-82. See also *Diagnosis*.

Medical Outcomes Study Short Form 36 (SF-36), 141

Medical problems, COPD-related. See *Comorbid conditions*.

Medical Research Council (MRC) Dyspnea Scale, 54, 55t, 227

Medications. See *Pharmacologic therapy*.

Men
 mortality rates from COPD, 19-20, 19, 20
 nomogram for predicting lung age, 86
 prevalence of COPD in, 21

Mental health, referrals for, 91t

Mental status, assessment in exacerbations, 262

Metabolic acidosis/alkalosis, 70

Metabolism, increased, 60, 118

Metaprel, 138t

Metaproterenol, 133, 138t, 147
 vs ipratropium, 148, 150

Metaproterenol sulfate, 138t

Metered dose inhalers (MDIs), 179t, 194-195, 197t

Methylxanthines, 191-194, 192t. See also *Theophylline*.
 action mechanisms, 128, 129, 191
 benefits vs risks, 191, 194
 drug-disease and drug-drug interactions, 191, 193t, 194
 indications for, 193, 194
 key points, 193-194
 side effects, 191

Metoprolol, 239

Minnesota Nicotine Withdrawal Scale, 106

MMPs (matrix metalloproteinases), 201, 239

Modified Borg Scale, 54, 55t

Monitoring. See *Follow-up and monitoring*.

Monoamine oxidase inhibitors, cautions for, 145

Moraxella catarrhalis, 258, 264

Morbidity, COPD-related
 costs of, 25, 25
 factors in, 111
 systemic effects and, 59-60

Mortality
 for chronic smokers, 93
 risks of inhaled anticholinergics, 159, 160-161

Mortality from COPD
 corticosteroid use associated with, 167
 corticosteroids, beneficial effect on, 173-177, 176
 costs related to, 25, 25
 from exacerbations, 89, 255, 257
 gender and, 19-20, 19, 20
 malnutrition associated with, 247
 mortality rates, 18-20, 19, 20
 predictors of
 BODE Index, 39
 IC/TLC, 39
 race and, 20
 reducing
 through antibiotics, 198
 through corticosteroid/bronchodilator combinations, 187-191, 188, 189, 190, 191
 through pulmonary rehabilitation, 114-115
 severe COPD, 277
 surgical procedures and, 214, 215-220
 systemic effects and, 59-60
 weight loss as risk factor, 118, 119

Motivation. See *Patient motivation*.

MRC (Medical Research Council) Dyspnea Scale, 54, 55t

Mucociliary dysfunction, 86, 88

Mucociliary transport, stimulation of, 135

Mucolytic agents, 198-199, 200t, 246
 not proven for exacerbations, 265

Mucous metaplasia, 35t

Mucus hypersecretion, 32, 259, 259t, 264-265

Multicomponent nature of COPD, 83-86, 88, 226

Muscarinic receptors, 128, 129, 147
 subtypes, 150, 151

Muscle mass, measurement of, 119-120

Muscle wasting and dysfunction, 45-47, 46t, 59, 241
 consequences of, 118
 measurement of, 119-120
 pathogenesis of, 118-119

Muscles
 deconditioning of, 11, 47, 241
 effect of pulmonary rehabilitation on, 111, 112

- Muscles (*continued*)
- strength
 - decreased, 45
 - increased, with theophylline, 191
 - Musculoskeletal disorders, 241-242
 - Myocardial infarction, 160
 - Myopathy, 241
- N*-acetylcysteine, 201
- Narcotics, 200t
- National Emphysema/COPD Association (NECA), 283
- National Emphysema Foundation, 283
- National Emphysema Treatment Trial (NETT), 215
- National Heart, Lung, and Blood Institute, 81, 283
- National Jewish Health Lung Line, 283
- National Lung Health Education Program (NLHEP), 81, 283
- Natural history of COPD, 43
- Nebulizer agents, 137t-140t, 145, 146, 179t
- Nebulizer devices, 196t
- NECA (National Emphysema/COPD Association), 283
- Neck vein distention, 58
- Neulin Depot, 192t
- Neutrophils, 35t, 36t, 43
 - in COPD exacerbations, 259, 259t
 - inhibition of recruitment/function, 135, 199
- NICE (National Institute of Clinical Excellence), 282t
- Nicotine gum, 101, 104t
- Nicotine inhaler, 101, 104t
- Nicotine-replacement therapy, 99-100, 101-103. See also *Smoking cessation*.
 - delivery systems, 101
 - prescribing information, 104t
 - side effects of, 101-103
- Nicotinic acetylcholine receptor partial agonist. See *Varenicline*.
- Nitrates, 239
- Nitric oxide
 - cautions concerning, 237
 - inflammation and, 35t
 - inhaled, for pulmonary hypertension, 237
- NLHEP (National Lung Health Education Program), 81, 283
- Nocturia, 245
- Nocturnal Oxygen Therapy Trial (NOTT), 121, 122
- Nomograms, for predicting lung age, 86, 87
- Noninvasive mechanical ventilation, 231, 265
- Noninvasive positive pressure ventilation (NPPV), 265
- Nonpharmacologic therapy, 111-126, 203. See also *Pulmonary rehabilitation*.
 - oxygen therapy, 120-123
 - pulmonary rehabilitation, 111-121
- Nortriptyline, 243
- NOTT (Nocturnal Oxygen Therapy Trial), 121, 122
- Nutrition, 118-120, 241
 - disorders of, 247-248
 - emphasis on, 88
 - interventions, 47, 120, 247
 - nutritional depletion, 45, 46t
 - nutritional status
 - assessment of, 119-120
 - as risk factor, 44, 118
 - nutritional supplementation, 120, 247-248
 - nutritional therapy, 118-120
- Obese patients, 118
- Obstructive sleep apnea, 246
- Occupational risk factors for COPD, 52t
- Occupational therapists, 115
- Older patients
 - aerosol device use by, 195
 - cognitive decline in, 243-244
 - COPD risk/prevalence and, 21, 226
- Omega-3 fatty acids, 247
- Osteoporosis, 56, 57, 60, 241-242
 - comorbid with COPD, 241-242
 - corticosteroids and, 167, 177, 241
 - management in COPD, 242t
- Overinflation. See *Hyperinflation*.
- Oxidative stress, 37, 60, 119, 201
 - COPD exacerbations and, 258
- Oximeters, 69
- Oximetry, pulse, 262, 263
- Oxis, 140t
- Oxitiropium bromide (Oxivent), 149t
- Oxivent (oxitropium bromide), 149t
- Oxygen saturation
 - in exacerbations, 262, 263
 - measuring, 69, 70, 262, 263
 - in sleep disorders, 246
- Oxygen therapy, 121-123. See also *Ventilation support*.
 - air travel and, 123
 - for cardiovascular disorders, 236, 238
 - clinical studies on, 121, 122
 - during exercise, 121-122, 123
 - for exacerbations of COPD, 263
 - for hypoxemia, 236, 238, 260-261
 - long-term, 122-123, 130
 - nocturnal, 121, 122
 - portable oxygen, 123
 - testosterone levels, impact on, 249
- Oxyhemoglobin saturation, 263
- Palliative care, 278, 279
- Panacinar (panlobular) emphysema, 32
- Panic control, 117
- Panic disorders, 243
- Panlobular emphysema, 32, 77
- Paroxysmal abdominal breathing, 262
- Pathogenesis of COPD, 34-38, 37
- Pathology of COPD, 31-34, 37. See also *Pathophysiology of COPD*.
 - chronic bronchitis, 32, 33
 - emphysema, 32, 33
 - histopathology, 40-41
 - small-airways obstruction, 32-34
- Pathophysiology of COPD, 31-49
 - airway inflammation, 34, 35t, 43
 - inflammatory cells, 36t
 - definition for diagnosis, 31
 - development and progression of COPD, 43-47
 - muscle wasting and dysfunction, 45-47, 46t
 - natural history of COPD, 43
 - pathogenesis, 34-38, 37
 - pathology, 31-34, 37
 - chronic bronchitis, 32, 33, 40-41
 - emphysema, 32, 40-41
 - histopathology, 40-41
 - small-airways obstruction, 32-34, 38

Pathophysiology of COPD (*continued*)
 physiologic alterations, 34-38, 37t
 airflow limitation, 34-38, 38t, 40-41
 gas-exchange abnormalities, 42-43
 hyperinflation, static and dynamic, 38-39
 reversibility with bronchodilators, 39-42
 systemic consequences of COPD, 45-47, 46t

Patient
 general approach to, 81-92
 relationship with PCP, 15, 88
 treatment decisions, advance directives, and end-stage care, 266, 277-279

Patient education
 on exacerbation prevention, 269t
 in pulmonary rehabilitation, 47, 117

Patient motivation
 for lung health, 83
 for pulmonary rehabilitation programs, 116
 for smoking cessation, 93, 96-99, 98t

Peak expiratory flow (PEF), 63-64
 Peak expiratory flow rate (PEFR), 134
 PEF (peak expiratory flow), 63-64

Percussion of the chest, 58

Performist (Formoterol fumarate inhalation solution), 140t, 146

Peripheral edema, 58, 59

Peripheral vascular disease, 57, 60

Peripheral vasodilation, 59

Pharmacologic stress testing, 239

Pharmacologic therapy, 127-212. See also *specific therapies*.
 action mechanisms of, 128, 129
 bronchodilation, production of, 128, 129
 combined therapies, rationale for, 128, 129t
 COPD stages, therapy for each stage, 130
 device selection in aerosol therapy, 194-195, 196t-197t
 effects of, 129t
 goals of, 127-128
 integration with patient care, 201-203, 202t
 key points, 129t, 202-203
 overview, 127-129, 129t
 for smoking cessation, 99-107
 specific therapies
 bronchodilator combinations, 161-167
 bronchodilators, 131-161
 corticosteroid/bronchodilator combinations, 178-191
 corticosteroids, 167-178
 future, 199-201
 methylxanthines, 191-194
 other, 195-199, 200t
 stepped-care approach, 201, 202t

Phlebotomy, to reduce blood viscosity, 238

Phosphodiesterase-4 (PDE₄) inhibitors, 199-201

Phyllocontin, 192t

Physical activity. See *Exercise*.

Physical examination, 57-60, 82
 for exacerbations, 262

Physical therapist, 89

Physicians, on pulmonary rehabilitation team, 115.
 See also *Primary care physicians*.

Physiologic alterations in COPD, 34-38, 37t
 PiM allele, 44-45

Pirbuterol (Maxair), 138t

PiZ/PiZZ alleles, 44-45

Plethysmograph, 66-67

Pleural effusion, 56

Pleuritic chest pain, 56

Pneumectomy, 214

Pneumonia
 as COPD exacerbation risk factor, 258, 258t
 immunization for, 88, 198, 269t
 risk, corticosteroid use and, 177-178, 189
Streptococcus pneumoniae, 258

Pneumothorax, 32, 56, 258t

Pollution, air, COPD risk and, 22-23

Polycythemia, 73-74, 235

Polyunsaturated fatty acids, 247

Post-bronchodilator FEV₁/FVC ratio, 31, 38t

Postobstructive atelectasis, 260

Prednisolone, 65

Prednisone, 167

Pregnancy, nicotine-replacement therapy and, 101

Prevalence of COPD, 18-21. See also *Risk factors for COPD*.
 age and, 21
 COPD definition and, 226
 in developing vs developed countries, 18-19
 factors in, 21
 gender and, 21, 24
 global, 18
 smoking rate impact on, 21-22, 22

Prevention and early detection, 14, 81-86
 of comorbid conditions, 235
 components of, 82
 screening questionnaire, 84t-85t

Primary care physicians (PCPs)
 communication and coordination, role in, 89
 COPD, reasons for concern about, 14-15, 81
 follow-up and monitoring by, 72
 general approach to COPD patient, 81-92
 guidelines for, 82
 management of comorbid conditions by, 235
 management of COPD by, 14-15, 25, 26, 88
 motivation for patient behavior change by, 15
 motivation for smoking cessation by, 93, 96-97
 positive attitude, importance of, 81
 referral to specialists, 72-73, 89, 90, 91t
 relationship with patient, 15, 88
 smoking cessation follow-up by, 97, 99

Productivity loss due to COPD, 24

Progressive symptom-limited exercise testing, 70-71

ProMeta, 138t

Prostacyclin analogs, 237

Protease inhibitors, 23, 44-45

Proteases, 201, 239, 259

Protein intake, 241

Protein metabolism, changes in, 46t, 119

Proteinases, 37

Proventil, 136t

Proventil HFA, 136t

Proximal airways, 38

Pseudodementia, 244

Psychiatric morbidity, 56, 60

Psychologists, on pulmonary rehabilitation team, 115

Pulmicort. See *Budesonide*.

Pulmonary Channel Healthcommunities.com, 284

Pulmonary Education and Research Foundation (PERF), 284
 Pulmonary embolism, 256
 Pulmonary function tests, 60-69, 262
 Pulmonary hypertension, 78, 235-237, 236t
 in COPD exacerbations, 260t
 Pulmonary obstruction. See *Airflow obstruction*.
 Pulmonary parenchyma. See *Lung parenchyma*.
 Pulmonary rehabilitation, 111-121, 130
 benefits of, 47, 112-115, 112t
 combined with pharmacotherapy, 131-132
 components of, 115-120
 defined, 111
 effect of cycle of deconditioning and inactivity, 111, 112
 for exacerbation prevention, 269t, 272
 exercise testing prior to, 69-71
 exercise training in, 116-117
 indications for, 231
 individual tailoring of, 115
 long-term effectiveness data, 121
 multidisciplinary team in, 115
 nutritional therapy, 118-120
 outcome assessment for, 120-121
 patient education in, 117
 patient selection for, 69, 116
 psychosocial and behavioral intervention, 117
 settings for, 120-121
 skeletal muscle function, impact on, 111, 112
 specialist referrals in, 91t
 Pulmonary thromboembolism, 68
 Pulmonary vascular pressure testing, 72
 Pulse oximetry, 262, 263
 Pulse rate, 59
 Purse-lipped breathing, 57
 Purulent sputum. See *Sputum production, purulent*.

Qtc interval, prolongation of, 145-146
 Quality of life (QOL)
 COPD threat to, 26
 in end-stage COPD, 277-278
 exacerbations, reduction by, 89, 255, 267
 health-related (HRQOL), 133, 135
 improved with bronchodilator use, 135, 141
 improved with combination therapy, 164-165, 166, 181, 184, 191
 improving
 through bronchodilators, 133, 135, 141, 146, 154, 158
 through combination therapy, 164-165, 166, 231
 through pharmacotherapy, 127
 through surgery, 215
 measures of, 73
 monitoring, 73
 nutritional depletion and, 45
 questionnaires, 73
 sleep quality impact on, 246
 Questionnaires, 73, 84t-85t, 229
 assessment of symptomatic benefit from treatment, 229t
 CRDQ, 73, 114
 SF-36 (Medical Outcomes), 141
 SGRQ, 73, 114, 141, 143, 146, 153
 Quibron-T, 192t
 Qvar, 170t

Race
 mortality rates from COPD, 20
 prevalence rates for COPD and, 18
 Radiation therapy, 244
 Radiography, 74-78
 computed tomography (CT), 76-78, 77, 214
 plain chest, 74-76, 75, 214
 for exacerbations, 262
 Raloxifene, 242t
 RANTES, 259t
 Reactive airway disease, 81
 Recombinant human growth hormone, 247
 Referral
 for pulmonary rehabilitation, 115-116
 to specialists, 72-73, 89, 90
 indications for, 90, 91t
 Rehabilitation
 exercise and conditioning, 241
 pulmonary. See *Pulmonary rehabilitation*.
 Residual volume (RV), 66, 68, 131
 Resources and associations, 281-284
 Respid, 192t
 Respiratory acidosis, 43, 70, 262
 hospitalization for, 267t
 mechanical ventilation for, 266t
 Respiratory arrest, 266t
 Respiratory failure, 69, 278
 Respiratory infections. See *Bacterial infections; Viral infections*.
 Respiratory muscles
 corticosteroid use and, 167
 function testing, 71-72
 training of, 117
 Respiratory physiologic alterations and abnormalities, 34-38, 37t
 Respiratory rate, 57
 Respiratory signs of COPD, assessment of, 57-58
 Respiratory specialists, 88, 89
 in end-of-life care, 278
 Respiratory stimulants, 200t
 Respiratory therapist, 115
 Rhinalar, 171t
 Rhinitis, 53t
 Rhinovirus, 257
 Rhonchi, 58
 Rib fractures, 242
 Right-heart failure (cor pulmonale), 58, 236t, 237-238, 262
 Right ventricular function, testing of, 72, 78
 Right ventricular hypertrophy, 58, 76, 78
 Risk factors for COPD, 21-24, 43-45, 81
 age/aging, 21, 23, 81
 air pollution, 22-23, 44
 demographic associations, 24. See also *Gender*.
 eliminating, 87
 environmental pollution, 81
 genetic factors, 23-24, 44
 history of exposure to, 51, 52t
 occupational, 52t
 reduction of, 130
 smoking, 21-22, 22, 52t, 81
 Roflumilast, 201
 Rotahaler, 170t
 RV (residual volume), 66, 68, 131

S pneumoniae, 258, 264
 Saint George's Respiratory Questionnaire. See *SGRQ*.
 Salamol, 136t
 Salbulin, 136t
 Salbutamol, 136t
 Salmeterol, 135-143, 140t. See also *Fluticasone/salmeterol (Advair/Advair Diskus)*.
 in combination
 with inhaled steroid fluticasone (Advair), 143, 178-182, 179t
 with theophylline, 163-164, 165
 in TRISTAN study, 168, 178-182, 180
 effects of, 135, 141, 143
 on mortality, beneficial, 173, 176-177
 efficacy, 135-143
 for exacerbations and severe COPD, 89, 272
 formulations
 salmeterol/fluticasone (Advair), 143
 Serevent, 140t
 onset and duration of action, 135
 vs ipratropium, 135-141, 142
 vs theophylline, 135
 vs tiotropium, 152-154, 154
 Salmeterol/fluticasone. See *Fluticasone/salmeterol (Advair/Advair Diskus)*.
 Salmeterol xinafoate (Serevent, Serevent Diskus), 135, 140t
 Screening for COPD
 prevalence rates from, 18
 questionnaire for, 84t-85t
 Secretions, mobilization and clearance of, 264-265
 Sedatives, 258t, 261
 Seizures, bupropion and, 103
 Selective serotonin reuptake inhibitors (SSRIs), 243
 Self-management, 117
 Self-paced exercise tests, 71
 Sepsis, 266t
 Serevent (salmeterol xinafoate), 135, 140t. See also *Salmeterol*.
 Serum albumin level, 257
 Severe COPD, management of, 89, 111, 130
 Severity classification and staging. See *Stages of COPD*.
 Sexual dysfunction, 248-249
 SF-36 (Medical Outcomes Study Short Form 36), 141
 SGRQ (St George's Respiratory Questionnaire), 73, 114
 improvements with bronchodilator use, 141, 143, 146, 153
 SHINE trial, 186-187
 Short-acting β_2 -agonists, 133-134, 136t-139t. See also *specific agents*.
 onset and duration of action, 134
 specific agents and dosing, 134, 136t-139t
 Shortness of breath. See *Dyspnea*.
 Shuttle-walking tests, 71, 116
 Sildenafil (Viagra), 237, 249
 "Silent zone," 38
 Single-breath technique, 68-69
 6-minute walk, 71, 116
 Skeletal muscle deconditioning, 11, 47, 241
 Skeletal muscle dysfunction, 241. See also *Muscle wasting and dysfunction*.
 Skeletal muscle strengthening, 191
 Sleep apnea, 72
 Sleep disorders, 245-246
 Sleep hygiene, 246
 Sleep quality, impaired, 56
 Sleep studies, 72, 246
 Slo-Bid, 192t
 Slo-Phyllin, 192t
 Small airways
 disease (bronchiolitis), 52
 function indicator, vital capacity as, 66
 inflammation of, 40-41, 52, 127
 obstruction, 32-34, 38
 Smoke, from home cooking and heating fuels, 52t
 "Smoker's cough," 51, 54
 Smoking
 addictiveness of, 93
 airflow limitation with, 43-44, 44
 COPD exacerbations and, 258
 COPD pathogenesis and, 37
 COPD prevalence rates and, 18, 19, 21, 22
 as COPD risk factor, 18, 21-22, 22, 43-44, 44, 45, 81-82, 127
 cough and sputum production, 54-56
 Fagerstrom test for nicotine dependence, 101, 102t
 FEV₁/FVC ratios for, 18, 43-44, 44
 as "fifth vital sign," 82
 gender and, 19
 history, inquiry about, 57, 82
 increase in, 21
 osteoporosis and, 56, 241
 percentage of smokers progressing to COPD, 43, 93
 premature deaths due to, 93
 pulmonary rehabilitation eligibility and, 116
 statistics, 18
 treaty on tobacco control, 21-22
 withdrawal symptoms, 97, 98
 Smoking cessation, 93-110
 aids for, 93
 algorithm for, 95
 assisting in, 96-97
 barriers to, 97-98
 benefits of, pulmonary, 93, 94, 127
 encouragement for, 96
 exacerbation prevention, role in, 267, 269t
 follow-up in, 97, 99
 guidelines for (USPHS), 93-94, 97-98, 99
 impact of/necessity for, 87
 lung cancer risk and, 244, 245
 motivation for, 93, 96-99, 98t
 in osteoporosis management, 242t
 pharmacotherapy for, 99-107
 bupropion, 100, 103, 104t
 nicotine-replacement, 99-100, 101-103, 104t
 prescribing information, 104t
 side effects of, 101-103
 varenicline (Chantix), 100, 103-107
 preoperative, 214
 as pulmonary rehabilitation component, 116
 quit date, setting, 96, 107
 relapse, and prevention of, 99, 100t
 strategies for, 93-97
 five A's, 94-96, 96t
 five R's, 98, 98t
 relapse prevention, 99, 100t
 success rates for, 99, 100
 weight gain and, 98, 100t
 withdrawal symptoms, anticipating and treating, 97, 98-99

- Smooth muscle, airway
 bronchodilator impact on, 128, 129, 147
 hyperplasia of, 34
 proliferation of, 135
- Smooth muscle, vascular, 237
- Social workers, on pulmonary rehabilitation team, 115
- Socioeconomic status, as risk factor, 44
- Spacers in aerosol devices, 147, 194, 197t
- Specialist care, referral for, 72-73, 89, 90
 indications for, 90, 91t
- Spinal kyphosis, 23
- Spiriva. *See* *Tiotropium*.
- Spirometry, 60-63, 82-83
 in assessment of therapy, 128
 baseline, 128
 COPD classification based on, 38t
 COPD staging, role in, 38t, 60, 62, 226-227, 228t
 in diagnosis, 51, 127, 226-227, 228t
 in exacerbation monitoring/evaluation, 267
 impaired, 61-62, 62
 importance of, 31, 82-83
 indices derived from, 60, 61
 normal, 61, 61
 performance of, 63
 preoperative, 213, 214
- Sputum production, 32, 52t, 54-56
 in chronic bronchitis, 56
 cough and, 54-56, 264-265
 in exacerbations of COPD, 256, 257, 264-265
 purulent, 55, 56
 antibiotics for, 198, 231, 264
 in exacerbations of COPD, 256, 264
 as symptom, 54-56
 volume of, 198, 256, 264-265
- SSRIs (selective serotonin reuptake inhibitors), 243
- St George's Respiratory Questionnaire. *See* *SGRQ*.
- Stable COPD, management of, 86-88
- Stages of COPD, 38t, 62, 228t
 based on FEV₁, 226
 based on spirometry, 38t, 60, 62, 226-227, 228t
 pharmacologic therapy for, 130, 202t
 prevalence data and, 20-21
 stepped-care approach, 201, 202t
- Static hyperinflation, 37t, 39
- Static lung volumes, 66-67, 67, 68
- Steady-state exercise tests, 71
- Stepped-care approach, 201, 202t
- Steroids. *See also* *Corticosteroids*.
 anabolic, 241
 replacement therapy for osteoporosis, 242t
 smoking and, 241
- Strength training, 117
- Streptococcus pneumoniae*, 258, 264
- Stress management, 117
- Stress testing, 239
- Stroke, 160
- SUN trial, 186-187
- Support groups, 117
 for smoking cessation, 100t
- Surgical therapy, 130, 213-224
 complications and risks, 213
 mortality, postoperative, 214
- Surgical therapy (*continued*)
 non-COPD related, 213-214
 patient selection for, 216t-217t, 221t
 preoperative smoking cessation, 214
 preoperative spirometry, 213, 214
 surgeries in COPD patient, 213-214
 types of
 bullectomy, 214-215, 216t-217t
 coronary artery bypass, 239-240
 lung resection, 213-214
 lung transplantation, 220, 221t
 lung volume-reduction (LVRS), 215-220, 218-219
- Sustained-release bupropion. *See* *Bupropion*.
- Symbicort, 169, 179t, 182-187, 183, 185
- Symptoms of COPD, 53-56
 assessing, 227-229
 chest pain and tightness, 56
 cough and sputum production, 54-56
 dyspnea, 52t, 53-56, 55t
 evaluation of, 53-56, 55t
 osteoporosis, 56
 progression of, 43-47
 reducing or relieving
 bronchodilators, 133, 135, 143, 158
 corticosteroid/bronchodilator combinations, 164, 191
 corticosteroids, 168
 pharmacologic therapy, 127, 227
 pulmonary rehabilitation, 113
 sleep disturbances, 56
 weight loss, 56
 wheezing, 56
- Systemic corticosteroids. *See* *Corticosteroids, systemic*.
- Systemic effects of COPD, 4t, 17, 45-47, 59-60, 238
- Systemic hypertension, 240-241
- Systemic side effects of β_2 -agonists, 146-147
- Systolic heart failure, 240
- T lymphocytes, 36t
- Tachypnea, 58
- TDI (transition dyspnea index), 181
- Team approach to COPD management, 89, 115
- Telmisartan, 240
- Terbutaline, 139t
- Testosterone, 45
 deficiency
 corticosteroid use and, 248
 osteoporosis and, 241
 sexual dysfunction and, 248
 replacement/supplementation, 242t, 249
- Tests for COPD patients, 60-72
 exercise, 69-71
 optional, 69-72
 pulmonary function tests, 60-69, 262
 required for all patients, 60-69
 stress, 239
- Theo-24, 192t
- Theo Dur, 192t
- Theochron, 192t
- Theochron SR, 192t
- Theofyllin, 192t
- Theolair, 192t

- Theophylline, 191-194
 action mechanisms, 129, 191
 agents and dosages, 192t
 benefits vs risks, 191, 194
 in combination therapy, 163, 193
 with salmeterol, 163-164, 165
 contraindications, for acute exacerbations, 263
 drug-disease and drug-drug interactions, 191, 193t, 194
 adenosine, 239
 calcium antagonists and, 241
 cytochrome P-450 inhibitors, 243
 SSRIs, 243
 indications for, 193, 194, 230
 key points, 193-194, 230
 long-acting, 192t
 short-acting, 192t
 side effects, 191, 230
 vs salmeterol, 135
- Thiazide diuretics, 242t
- Third National Health and Nutritional Examination Survey, 18
- Thoracic surgeon, referral to, 91t
- Thoracotomy, 213
- Tidal volume (VT), 54, 195
 VD/VT, 71
- Tiotropium (Spiriva), 149t, 150-159, 229
 action mechanism, 150, 151
 adverse effects, 158, 159
 in combination
 with albuterol, 160
 with salmeterol or fluticasone/salmeterol, 164-167, 166
 duration of action, 150, 160
 effects of, 151, 154-158
 exercise capacity/endurance, 113, 155-157, 156, 157
 lung volumes, 154-155, 155, 160
 efficacy, 151-159, 152
 Dutch/Belgian Tiotropium Study Group, 152, 153
 for exacerbation prevention, 272
 half-life, 150
 key points, 160
 tolerability and safety, 151, 159
 UPLIFT study, 158-159, 159
 vs fluticasone/salmeterol, 270-272
 vs salmeterol, 152-154, 154
- TLC (total lung capacity), 66, 68, 131
- TLCO (diffusing capacity of carbon monoxide), 68-69
- TNF α . See *Tumor necrosis factor alpha*.
- Tobacco smoke. See *Smoking*.
- TORCH (Towards a Revolution in COPD Health) trial, 128, 176-177
 survival and mortality in, 187-191
- Tornalate (Bitolterol), 139t
- Total lung capacity (TLC), 66, 68, 131
- Towards a Revolution in COPD Health. See *TORCH trial*.
- Transdermal patch, nicotine-replacement, 101, 104t
- Transition dyspnea index (TDI), 181
- Travel, oxygen therapy during, 123
- Treadmill exercise, 116
- Treadmill tests, 70-71, 239
- Treatment. See also *Management of COPD*.
 algorithm, 83
 assessing response to, 227-229
 goals, 111
- Treatment (*continued*)
 guidelines, 82, 83, 225-233
 key interventions, 14
- Treprostinil, 237
- Trial of Inhaled Steroids and Long-Acting β_2 -Agonists (TRISTAN), 168, 178-182, 180
- Trials. See *Clinical trials*.
- Triamcinolone (Azmacort), 171t
 clinical studies, 168, 172, 174
- Tricuspid incompetence, 59
- Tricyclic antidepressants, cautions for, 145
- TRISTAN (Trial of Inhaled Steroids and Long-Acting β_2 -Agonists), 168, 178-182, 180
- Tuberculosis
 airflow limitation in, 53
 history of, 57
- Tumor necrosis factor alpha (TNF α), 35t, 45, 199, 241
 in COPD exacerbations, 259
- Ultrasonic nebulizers, 196t
- Unidur, 192t
- Uniphyllin, 192t
- UPLIFT (Understanding Potential Long-term Impacts on Function With Tiotropium) study, 158-159, 159
- Urgent care, 243
- Urinary retention, 148
- Urologist, 249
- US COPD Coalition, 284
- \dot{V}/\dot{Q} . See *Ventilation-perfusion*.
- Vaccinations, 87-88, 130, 195-198, 269t
- Valsartan, 240
- Vanceril, 170t
- Vanceril DS, 170t
- Varenicline (Chantix), 100, 103-107
 efficacy of, 103-107, 105, 108
 seven-day point prevalence of abstinence, 106-107, 108
 vs bupropion, 105-106, 105
- Vascular disease. See *Cardiovascular disorders*.
- Vasodilators, 200t
- VC. See *Vital capacity*.
- VD/VT (dead space:tidal volume ratio), 71
- Ventilation-perfusion (\dot{V}/\dot{Q})
 mismatching, 37t, 42-43, 255, 260
 ratios, 42, 260-261
- Ventilation support. See also *Oxygen therapy*.
 in end-stage disease, 277-278
 exacerbation treatment with, 231, 265-266
 invasive, 265-266, 266t
 indications for, 266t
 survival to hospital discharge with, 278
 noninvasive, 231, 265
 patient decisions about end-of-life care, 277-278
- Ventodisk, 136t
- Ventolin, 137t
- Ventolin Rotacap, 137t
- Ventricular hypertrophy, 58, 76, 78
- Vertebral fractures, 242
- Viagra (sildenafil), 237, 249
- Viral infections, 257-258, 258t, 259t
- Vital capacity (VC), 63, 66, 242

Vitamin D supplements, 242t

Volmax, 137t

VT. See *Tidal volume*.

Weakness, 56

Weight categories (normal, underweight, overweight, obese), 119

Weight gain

decreased COPD mortality and, 120

smoking cessation and, 98, 100t

Weight loss, 56, 59-60, 118-120. See also *Muscle wasting and dysfunction*.

consequences of, 118

COPD mortality and, 118, 119

defined, 119

involuntary, as indication for nutritional supplementation, 120

mechanisms of, 59-60

pathogenesis of, 118-119

prevalence in COPD, 45, 118

Wheezing, 56, 58

Women

aggressive/progressive course of COPD in, 24

estrogen, anti-inflammatory effect of, 24

gender as risk factor, 24

mortality rates from COPD, 19-20, 19, 20

nomogram for predicting lung age, 87

prevalence of COPD in, 21, 24

Work of breathing

in COPD exacerbations, 260, 260t, 261

in COPD (increased), 39, 43

oxygen therapy effect on, 121

World Health Organization (WHO), 284. See also *GOLD*.

Framework Convention on Tobacco Control, 21-22

global prevalence of COPD, 18

X-rays. See *Radiography*.

Xopenex (levalbuterol), 138t